For the first time since 2023, LVMH (LVMUY.US) regains its position as the top market value in Europe.
Luxury goods group LVMH has seen its market value rise by 8.3% since the beginning of the year, reclaiming the title of Europe's largest market value company.
Luxury goods group LVMH (LVMUY.US) has seen its market value rise by 8.3% since the beginning of the year, regaining the title of Europe's largest market value company, surpassing Novo Nordisk A/S Sponsored ADR Class B (NVO.US) - whose market value has dropped in the past few weeks due to the disappointing weight loss results of a new experimental weight loss drug.
This is the first time LVMH has received this honor since 2023. In addition to LVMH and Novo Nordisk A/S Sponsored ADR Class B, other companies in the top ten of Europe's market value rankings include: ASML Holding NV ADR (ASML.US), SAP (SAP.US), L'Oral (HESAY.US), Roche (RHHBY.US), Accenture Plc Class A (ACN.US), Nestle (NSRGY.US), Astrazeneca PLC Sponsored ADR (AZN.US), and Novartis AG Sponsored ADR pharmaceuticals (NVS.US).
Under the leadership of Bernard Arnault, LVMH controls approximately 75 well-known brands, covering a wide range of categories such as fashion, wines and spirits, perfumes and cosmetics, watches and jewelry. These brands include Dior, Givenchy, Tiffany & Co., Sephora, Stella McCartney, Hennessy, Tag Heuer, Bulgari, and Louis Vuitton.
Looking ahead, LVMH has developed a strategy to strengthen its digital infrastructure and customer experience, with an expected 25% of personal luxury goods to be sold online. The company also aims to target young consumers and expand global partnerships, including collaboration with F1.
Analyst Eugenio Catone believes that LVMH is currently undervalued due to temporary market fluctuations. He points out that LVMH's strong competitive advantage and brand awareness remain unchanged, "the current undervaluation provides a buying opportunity, and with improving market conditions and sustained demand for luxury goods, it is likely to see a significant increase."
Related Articles

New stock preview | The core variety has obvious advantages in long-term innovation, can Yinnuo Pharmaceuticals support its valuation with the commercialization of single product?

HK Stock Market Move | XPENG-W(09868) falls more than 4%, G7 starting price is 195,800 yuan, further lower than the previous pre-sale price.

HK Stock Market Move | Some concept stocks of innovative drugs are rising, and two departments have issued documents to promote the development of innovative drugs. Citi believes that the sector will usher in multiple catalysts in the second half of the year.
New stock preview | The core variety has obvious advantages in long-term innovation, can Yinnuo Pharmaceuticals support its valuation with the commercialization of single product?

HK Stock Market Move | XPENG-W(09868) falls more than 4%, G7 starting price is 195,800 yuan, further lower than the previous pre-sale price.

HK Stock Market Move | Some concept stocks of innovative drugs are rising, and two departments have issued documents to promote the development of innovative drugs. Citi believes that the sector will usher in multiple catalysts in the second half of the year.
